Default mode network dysfunction in Down Syndrome - Down syndrome (DS), the most common genetic cause of intellectual disability, form the largest population
with a genetic predisposition in midlife to develop Alzheimer’s disease (AD). Virtually everyone with DS exhibit
neurofibrillary tangles (NFTs) containing-tau and β-amyloid (Aβ) plaques similar to AD by the fourth decade of
life, which increase with age. Greater than 70% of people with DS ultimately develop dementia, making this
population an excellent naturally-occurring human model for the study of the pathogenesis of dementia with
translation to AD. Although NFT pathology is tightly linked to the degree of dementia in both AD and DS
compared to Aβ plaques, the cellular mechanisms underlying cognitive decline in DS remain largely unexplored.
The goal of this project is to elucidate the molecular and cellular events underlying the selective vulnerability of
frontal cortex (FC) and precuneus (PreC) pyramidal neurons. These two interconnected hubs of the default mode
network (DMN) are involved in episodic memory and self-awareness and are dysfunctional in AD and DS. We
recently reported that people with DS with dementia display a greater number of NFTs in FC pyramidal neurons
containing advanced tau pathology compared to those without dementia. Interestingly, we also found that FC
NFT-positive neurons in DS with dementia display a different transcriptomic signature compared to non-
demented DS, despite having similar FC plaque loads between the DS groups. These findings suggest a key
role for tau pathobiology in the onset of dementia in DS. Interestingly, neuronal degeneration is manifested by a
confluence of intracellular events leading to alterations in tau mRNA splicing before the onset of clinical
symptoms. Recent evidence demonstrated that mislocalized splicing of U1 small nuclear ribonucleoproteins
(snRNPs) are associated with NFTs in sporadic and familial AD and DS, but not other tauopathies. We now
report greater defects in splicing proteins, particularly those associated with alternative splicing of tau, that occur
in the more advanced stages of NFT development in the FC in DS with dementia compared to those without
dementia. In this project, we will investigate the molecular pathobiology of selectively vulnerable DMN neurons
in people with DS with and without dementia using conceptually and technically innovative approaches: splicing
antibodies during the post-translational progression of tau evolution, single population microarray and RNA
transcriptomics, combined with functional gene pathway analysis. This proposal expects to lay the foundation
for a wide range of potential interventions for the design of novel drugs and biomarkers for the prevention of
dementia in DS with translation to AD.